Biomarin Pharmaceutical (BMRN) Other Non-Current Assets (2009 - 2026)

Biomarin Pharmaceutical has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $276.4 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 17.3% year-over-year to $276.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.4 million (up 17.3% YoY) and the FY2025 annual result came in at $277.0 million, up 10.21% from the prior year.
• Other Non-Current Assets held at $276.4 million in Q1 2026, from $277.0 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $277.0 million in Q4 2025 and troughed at $144.2 million in Q2 2023.
• A 5-year average of $199.7 million and a median of $184.8 million in 2024 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets dropped 5.03% — and 2024, when it surged 46.55%.
• Tracing BMRN's Other Non-Current Assets over 5 years: stood at $176.2 million in 2022, then slipped by 2.67% to $171.5 million in 2023, then jumped by 46.55% to $251.4 million in 2024, then climbed by 10.21% to $277.0 million in 2025, then decreased by 0.23% to $276.4 million in 2026.
• Business Quant data shows BMRN's Other Non-Current Assets at $276.4 million in Q1 2026, $277.0 million in Q4 2025, and $270.8 million in Q3 2025.